Background
Glioblastoma multiforme (GBM) remains one of the most aggressive and lethal primary brain tumors, with limited effective therapeutic options. The identification of novel molecular targets is critical to advancing treatment strategies. UniProt entry Q00526 corresponds to a human protein whose role in GBM biology is not well characterized. Preliminary expression profiling suggests differential regulation of Q00526 in GBM tissues compared to normal brain, indicating it may contribute to tumor pathophysiology. However, no clinical programs targeting Q00526 have been registered to date, highlighting it as a putative target that warrants experimental validation.
Data-mining rationale
This candidate emerged from a systematic cross-referencing approach that integrated UniProt’s reviewed human protein entries annotated for glioblastoma multiforme with a comprehensive reanalysis of 724 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). Several GEO datasets (GDS:200317497, GDS:200273558, GDS:200320501, GDS:200318047, GDS:200318046) included expression profiles relevant to GBM and showed signals implicating Q00526. These datasets provide a rich resource for exploring gene expression alterations in GBM, and Q00526’s recurrent appearance across multiple independent studies supports its candidacy as a molecular target.
Why prior analyses may have missed this
Many of the original GEO microarray studies predate the widespread adoption of modern empirical-Bayes statistical methods such as limma, which improve sensitivity and specificity in detecting differentially expressed genes while controlling for false discovery rates. Earlier analyses often lacked rigorous multiple-testing correction, potentially overlooking subtle but biologically meaningful expression changes. Consequently, Q00526 may have been underappreciated or missed in prior GBM transcriptomic analyses. A re-analysis of these datasets applying limma with Benjamini-Hochberg false discovery rate correction could more robustly identify Q00526’s differential expression and clarify its relevance.
Reasoning for further validation
Given the preliminary but consistent expression signals for Q00526 in GBM across multiple datasets, several experimental steps are warranted to validate its candidacy as a putative target. First, re-analyzing the matched GEO datasets using limma and stringent multiple-testing correction will refine the statistical evidence for differential expression. Second, validation of Q00526 expression in independent GBM cohorts by quantitative PCR would confirm reproducibility. Third, assessing tissue specificity through resources such as GTEx and the Human Protein Atlas will contextualize its expression pattern in normal versus tumor tissue. Fourth, bioinformatic pathway analyses using STRING or OmniPath can elucidate potential functional interactions and signaling pathways involving Q00526. Finally, if validated, evaluating druggability via databases like DGIdb and ChEMBL may inform future therapeutic exploration. Collectively, these steps will clarify whether Q00526 represents a viable molecular target in GBM deserving of further preclinical investigation.